Multiple core drugs are losing patent protection over the coming years, carving an eventual crater in revenue. Newer, growing drugs should help fill that hole, and Cobenfy is a wild card with huge potential.

BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.

Pre-Market Stock Futures: Futures are trading lower as we wrap up the holiday-shortened week that gave us a little taste of just about everything. While Walmart posted results that beat expectations, its forward guidance and outlook fell short of Wall Street's expectations, and the stock was down from the opening bell to the close. All... Here Are Friday's Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More.

A crucial oil and gas infrastructure company has a stock with a 5.9% yield on its dividend. A veteran pharmaceutical giant pays out a dividend yielding a generous 4.2%.

Bristol-Myers: I'm Buying Post Earnings

AbbVie is a Dividend King, poised for strong growth with Rinvoq and Skyrizi. Eli Lilly has taken control of the obesity drug market, with major possibilities ahead.

Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favorite is the 49% year-over-year increase in Breyanzi sales to $392 million in Q4.

FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026.

There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That's a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America's 50 states have more millionaires than others. By the process... This State Has More Millionaires Per Capita Than Any Other.

BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.